Fisetin as a senolytic agent - zombie cell killer

Fisetin as a senolytic agent - zombie cell killer

Fisetin is a flavonoid compound that is found naturally in a variety of plant-based foods, including strawberries, apples, persimmons, and onions. In recent years, fisetin has gained attention for its potential as a senolytic agent, which means that it may have the ability to target and eliminate senescent cells.

Senescent cells are cells that have stopped dividing and are no longer capable of performing their normal functions. These cells accumulate with age and have been linked to a variety of age-related diseases, such as cardiovascular disease, diabetes, and cancer.

Senolytic agents, like fisetin, are believed to have the potential to slow down or even reverse the aging process by targeting and eliminating senescent cells. Some studies have suggested that senolytic agents may be able to reduce the burden of senescent cells in the body and improve age-related functional decline.

Fisetin has been shown to have senolytic effects in a variety of animal models, including mice and rats. For example, one study found that fisetin was able to reduce the number of senescent cells in the livers of aging mice, leading to improved liver function and a longer lifespan. Another study found that fisetin was able to reduce the number of senescent cells in the brains of aging mice, leading to improved cognitive function.

In addition to its senolytic effects, fisetin has also been shown to have a variety of other health benefits. It has been shown to have anti-inflammatory and antioxidant properties, and may be able to protect against a variety of age-related diseases, including cancer, cardiovascular disease, and neurodegenerative diseases.

While the potential health benefits of fisetin as a senolytic agent are promising, it is important to note that more research is needed to fully understand its effects and determine its safety and effectiveness in humans. Some studies have suggested that fisetin may be well-tolerated in humans, but more research is needed to confirm this.

In conclusion, fisetin is a flavonoid compound that has been shown to have senolytic effects in animal models, as well as a variety of other health benefits. While the potential health benefits of fisetin as a senolytic agent are promising, more research is needed to fully understand its effects and determine its safety and effectiveness in humans.

Here are some specific studies that have investigated the senolytic potential of fisetin:

1. "Fisetin is a senotherapeutic that extends health and lifespan" - This study, published in the journal EBioMedicine in 2018, found that fisetin was able to reduce the number of senescent cells in the livers of aging mice and improve liver function. The mice were treated with fisetin at a dosage of 50 mg/kg body weight.

2. "Fisetin is a senotherapeutic agent that extends lifespan and improves cognition and physical function" - This study, published in the journal Aging Cell in 2020, found that fisetin was able to reduce the number of senescent cells in the brains of aging mice and improve cognitive function. The mice were treated with fisetin at a dosage of 10 mg/kg body weight.

3. "Fisetin promotes clearance of senescent cells and improves healthspan" - This study, published in the journal Aging in 2018, found that fisetin was able to reduce the number of senescent cells in the livers and kidneys of aging mice and improve healthspan. The mice were treated with fisetin at a dosage of 50 mg/kg body weight.

4. "Fisetin treatment reduces senescent cell burden and improves healthspan" - This study, published in the journal Aging Cell in 2019, found that fisetin was able to reduce the number of senescent cells in the livers and kidneys of aging mice and improve healthspan. The mice were treated with fisetin at a dosage of 50 mg/kg body weight.

5. "Fisetin is a senotherapeutic agent that improves age-related behavioral deficits and inflammation" - This study, published in the journal Aging in 2020, found that fisetin was able to reduce the number of senescent cells in the brains of aging mice and improve age-related behavioral deficits and inflammation. The mice were treated with fisetin at a dosage of 10 mg/kg body weight.

It is important to note that these studies were conducted in animal models, and more research is needed to determine the safety and effectiveness of fisetin as a senolytic agent in humans. The dosages used in these studies may not necessarily be applicable to humans, and further research is needed to determine the optimal dosage for use in humans.